Spike Big Pharmacy to "Brainstorm"
Release time:
2020-07-22
Peak Pharmacy conducts "Brainstorming "
"I think our big pharmacy has expensive drug purchase price and single variety, so we need to further improve the variety structure. " "We hope that when the company makes some major decisions, it can communicate in advance so that we can have the knowledge and voting rights. " April# December , in the conference room of Jianfeng Building, the management personnel of Jianfeng Pharmacy and the store managers of direct stores and franchise stores were divided into five groups according to different positions, each forming a circle. The discussion was very heated. This is the "Brainstorm " held by Spike Big Pharmacy at .
In recent years, the state's policies on the pharmaceutical industry have been frequent, the competition in the pharmaceutical retail industry is fierce, and the profit space of pharmacies is getting smaller and smaller. At present, Jianfeng Pharmacy has the current situation of small scale, low gross profit margin of products, sluggish internal operation performance and low employee satisfaction. For this reason, Jianfeng Pharmacy organized this "Brainstorming " to jointly discuss the existing problems and deficiencies and explore the future development direction through collective wisdom, so as to promote the improvement of management and the development of the enterprise. At the meeting site of
, the five groups of personnel of Jianfeng Pharmacy held heated discussions from the aspects of internal management, store image, procurement, team culture, products, etc. in combination with the development of the pharmacy and their own work practice, looking for the problems existing in the work and analyzing the crux of the problem. After discussion, each group put forward the most need to improve the 5 or 6 questions. Before the start of "brainstorming " , the participants also put forward their own opinions and suggestions in the form of anonymous, aiming at the shortcomings and breakthroughs of large pharmacies. After summarizing, a total of questions and suggestions 60 are listed. Jiang Xiaomeng, chairman of
Group Company and chairman of Pharmaceutical Company, participated in the "Brainstorming " and answered common questions raised by everyone. He asked large pharmacies to have clear peak characteristics and drive the development of large pharmacies with professional, quality and brand drugs. Through the overall store image and after-sales service to retain customers and increase customer stickiness; Establish a set of internal management processes that respond quickly and smoothly; To strengthen procurement management, procurement personnel should have a keen sense of smell and maintain good customer channels based on the principle of complete varieties, increase negotiations on variety structure, quantity, price, etc.; make appropriate changes to the new system procedures, strengthen staff training, so that employees are familiar with and adapt to the use of the new system; further strengthen team and cultural construction. For, Jiang Xiaomeng hopes that the management team of the large pharmacy will seriously solve the problems raised at the meeting, so that the large pharmacy can be better developed and improved.
It is understood that the peak pharmacy will also hold a meeting in the near future to implement solutions to various problems raised in the activity. (Reporter Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page